AsianScientist (Jun. 22, 2020) – A prescription digital therapeutic for the treatment of adults with substance use disorder has received authorization from the Health Science Authority (HSA) of Singapore.
Developed by US software-based digital therapeutics company Pear Therapeutics, Inc., reSET is a 12-week prescription treatment for substance use disorder, which is a chronic, relapsing disease caused by the recurrent use of alcohol or drugs, or both.
Prescription digital therapeutics, or PDTs, are a new class of therapeutics. Similar to traditional biologics or drugs, they must demonstrate safety and efficacy in randomized clinical trials, receive labeled claims from health regulators and be prescribed by a physician.
“This first authorization of a PDT outside the US represents an important milestone for Pear and builds on the embrace of PDTs for the treatment of serious diseases like substance use disorder. We look forward to expansion of PDTs to Asia, beginning with providing patients and providers access to reSET in Singapore,” said Dr. Corey McCann, president and CEO of Pear Therapeutics.
According to the company’s press statement, reSET offers interactive treatment modules that deliver cognitive behavioral therapy, fluency training to reinforce proficiency and contingency management. Through a clinician dashboard, clinicians can follow patient-reported substance use, cravings and triggers.
reSET will be used in conjunction with outpatient clinician-delivered care and be distributed by local partners to eligible patients in Singapore.
Source: Pear Therapeutics; Photo: Sam Albury/Unsplash.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.